Anzeige
Mehr »
Samstag, 21.06.2025 - Börsentäglich über 12.000 News
500 % Kursplus seit Januar. 462 g/t Goldgehalte. Mrd.-Investoren an Bord. Dieser finnische Junior wird heiß!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JJ99 | ISIN: US04962H5063 | Ticker-Symbol: YAG2
Tradegate
19.06.25 | 20:10
0,705 Euro
+2,77 % +0,019
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ATOSSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ATOSSA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6700,71012:46
0,6730,70020.06.

Aktuelle News zur ATOSSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.06.Ascendiant Capital raises Atossa Genetics stock price target to $7.5018
05.06.Atossa Therapeutics bei Jefferies-Konferenz: Strategische Schritte gegen Brustkrebs26
20.05.Atossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22317SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines...
► Artikel lesen
14.05.Atossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen258Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics...
► Artikel lesen
13.05.Atossa Therapeutics GAAP EPS of -$0.05 beats by $0.016
13.05.ATOSSA THERAPEUTICS, INC. - 10-Q, Quarterly Report3
13.05.ATOSSA THERAPEUTICS, INC. - 8-K, Current Report1
13.05.Atossa Therapeutics Inc: Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update189Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication Enhanced (Z)-endoxifen intellectual property portfolio with three new...
► Artikel lesen
ATOSSA THERAPEUTICS Aktie jetzt für 0€ handeln
05.05.RedChip Companies, Inc.: Atossa Therapeutics and Ainos Interviews Aired on the RedChip Small Stocks, Big Money Show on Bloomberg TV330ORLANDO, FL / ACCESS Newswire / May 5, 2025 / RedChip Companies aired interviews with Atossa Therapeutics, Inc. (Nasdaq:ATOS) and Ainos, Inc. (Nasdaq:AIMD) on the RedChip Small Stocks, Big Money show...
► Artikel lesen
30.04.Atossa wins U.S. patent related to multiple formulation of lead asset5
30.04.Atossa Therapeutics secures new patent for breast cancer drug7
30.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio165SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast...
► Artikel lesen
29.04.Atossa stellt Phase-3-Studie zur Brustkrebsprävention vor11
29.04.Atossa outlines phase 3 trial for breast cancer prevention2
29.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025193SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast...
► Artikel lesen
22.04.Atossa Therapeutics sichert neues Patent für Brustkrebsbehandlung30
22.04.Atossa Therapeutics secures new patent for breast cancer treatment4
22.04.Atossa Therapeutics announces issuance of U.S. patent3
22.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio212SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast...
► Artikel lesen
14.04.Nona Biosciences and Atossa team up to discover breast cancer therapies9
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,11